Compound ID | 1959

Update compound information

ETX-0282

Class: Beta-lactam + beta-lactamase inhibitor

Agent Type: Synthetic; Small molecule; Direct acting; Antibiotic adjuvant;
Mechanism of action: Cell wall synthesis inhibitor. Binds reversibly to the beta-lactamase in the active site, inhibits class A, C, D and weakly inhibits penicillin binding protein 2 in Enterobacteriaceae
Combined with other compounds: Yes
Description: Synthetic compound. Isopropyl ester prodrug of ETX-1317. In clinical development in fixed combination with cefpodoxime proxetil. Oral application
Institute where first reported: Entasis Therapeutics, Innoviva
Year first mentioned: 2019
Highest development stage: Phase 1 (as of 2022)
Development status: Active
Chemical structure(s):
Click here for structure editor
Molecular weight: 315.3
Iso. SMILES: CC1=C[C@@H](N2C[C@@H]1N(C2=O)O[C@@H](C(=O)OC(C)C)F)C(=O)N
InChI Key: OMNVFPBGXYKTDB-UTLUCORTSA-N
Can. SMILES: CC(C)OC(=O)[C@@H](F)ON1[C@H]2CN([C@H](C=C2C)C(=O)N)C1=O
InChI: InChI=1S/C13H18FN3O5/c1-6(2)21-12(19)10(14)22-17-9-5-16(13(17)20)8(11(15)18)4-7(9)3/h4,6,8-10H,5H2,1-3H3,(H2,15,18)/t8-,9+,10+/m1/s1
External links:
PubChem link: https://pubchem.ncbi.nlm.nih.gov/compound/146170992
Guide to Pharmacology: ETX1317
Citations:
  • https://pubmed.ncbi.nlm.nih.gov/33291867/
  • https://pubs.acs.org/doi/10.1021/acsinfecdis.0c00020
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927146/

    • AntibioticDB is supported by GARDP.

    If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

    The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.